首页 / 资料库 / 文献详情

Research on Asian Prescription Patterns (REAP): Focusing on Data from Japan

Naotaka Shinfuku

2014臺灣精神醫學Medicine被引 6

出版方页面 →

摘要

Since 2001, Asian psychiatrists have carried out collaborative research on the prescription patterns of psychotropic drugs in Asia (REAP). Investigators, who participated in the survey in 2001 and 2004, were from China, Hong Kong, Japan, Korea, Singapore, and Taiwan. In 2008, investigators from India, Malaysia, and Thailand also joined this research. All investigators collected the data based on a unified questionnaire-based research protocol. More than 6,000 prescriptions of schizophrenic inpatients, (around 2,000 prescriptions each in 2001, 2004, and 2008), were analyzed and compared. The results have yielded that Japan has notable high-dose antipsychotic prescription and high frequency of polypharmacy than other participating countries and areas, that the availability of particular drugs differs greatly from country to country, and that there has been a major shift in the prescriptions from first-generation antipsychotics (FGAs) to second-generation antipsychotics (SGAs) in all participated Asian countries from 2001 to 2008. This shift has been accompanied by changes in side effects and by the use of other psychotropic drugs. These findings have been reported in more than 30 international journals. In 2004, REAP members surveyed the prescription patterns of antidepressants and did a follow up survey in 2013. More than 200 psychiatrists of 40 psychiatric institutions from 10 countries and areas in Asia participated in the recently concluded 2013 survey. The goal of REAP has been to improve prescription patterns of psychotropic drugs in those participated Asian countries. REAP has potential to promote collaborative research in psychiatry among developed and developing countries in Asia.

引用本文(GB/T 7714)

Naotaka Shinfuku. Research on Asian Prescription Patterns (REAP): Focusing on Data from Japan[J]. 臺灣精神醫學, 2014.

引文网络

参考文献与被引分析加载中…

本站仅收录题录与摘要供学习参考,全文版权归属出版方;如有侵权请联系我们删除。